Horizon Therapeutics

Horizon Therapeutics plc
FormerlyHorizon Pharma plc
TypeSubsidiary
Nasdaq: HZNP
IndustryPharmaceutical
Founded2005 (2005)
Headquarters
Key peopleTimothy P. Walbert (chairman, president & CEO)

Paul W. Hoelscher (CFO)
Andy Pasternak (CBO)

Jeffrey W. Sherman, M.D. (CMO)
RevenueIncrease US$3.63 billion (2022)
Increase US$617 million (2022)
Decrease US$521 million (2022)
Total assetsIncrease US$9.11 billion (2022)
Total equityIncrease US$5.07 billion (2022)
Number of employees
2,115 (2022)
ParentAmgen
Websitehorizontherapeutics.com
Footnotes

Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.